Catheter PrecisionFRA:4RM 32 Return-on-Tangible-Equity is 0.00% as of Mar. 2026. GuruFocus rates FRA:4RM with a GF Score™ of 32/100 and a GF Value™ of €125.93. The stock has 7 warning signs investors should review. Among 757 Medical Devices & Instruments companies, Catheter Precision ranks worse than 132100.26% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Catheter Precision's annualized net income for the quarter that ended in Mar. 2026 was €-5.82 Mil. Catheter Precision's average shareholder tangible equity for the quarter that ended in Mar. 2026 was €-13.20 Mil. Therefore, Catheter Precision's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was N/A%.
The historical rank and industry rank for Catheter Precision's Return-on-Tangible-Equity or its related term are showing as below:
FRA:4RM's Return-on-Tangible-Equity is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 4.09 * Ranked among companies with meaningful Return-on-Tangible-Equity only.
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Catheter Precision Return-on-Tangible-Equity Related Terms
Catheter Precision Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Catheter Precision's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4RM vs ALURD, BJDX, AMIX: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Catheter Precision's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Catheter Precision Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Catheter Precision's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Catheter Precision's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 0.00% mean?
Catheter Precision (FRA:4RM) has a Return-on-Tangible-Equity of 0.00% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Catheter Precision and its competitors. According to the industry distribution chart, Catheter Precision ranks #999999 out of 757 companies in the Medical Devices & Instruments industry.
Is Catheter Precision's Return-on-Tangible-Equity too high?
Catheter Precision's current Return-on-Tangible-Equity is 0.00%. Based on the distribution chart, Catheter Precision ranks #999999 out of 757 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Catheter Precision has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Catheter Precision's Return-on-Tangible-Equity compare to ALURD and BJDX?
According to the Medical Devices & Instruments industry distribution chart, Catheter Precision ranks #999999 out of 757 companies for Return-on-Tangible-Equity. This places Catheter Precision in the lower half of its industry. The industry median Return-on-Tangible-Equity is 4.09. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.09, based on 757 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Catheter Precision and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Catheter Precision's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Catheter Precision stock overvalued right now?
Catheter Precision (FRA:4RM) has a current Return-on-Tangible-Equity of 0.00%. The stock's GF Value™ is €125.93, compared to a current price of €100.89 — trading 19.9% below its estimated fair value. The current Return-on-Tangible-Equity is 0.00%. Catheter Precision's overall GF Score™ is 32/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Catheter Precision (FRA:4RM), the current Return-on-Tangible-Equity is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Catheter Precision (FRA:4RM) Overvalued in 2026?
Based on GuruFocus' analysis, Catheter Precision stock appears to be undervalued.
The current stock price of €100.89 is trading 19.9% below its estimated GF Value™ of €125.93.
Key valuation signals for FRA:4RM:
Return-on-Tangible-Equity: 0.00%
GF Value™: €125.93 vs. price of €100.89 (19.9% below fair value)
No single metric tells the full story. See the FRA:4RM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Catheter Precision Inc is engaged in the design, manufacture, and sale of medical technologies focused in the field of cardiac electrophysiology, or EP. The company's two primary products include the VIVO System and LockeT. The VIVO System, which is an acronym for View into Ventricular Onset System(VIVO or VIVO System), is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its newest product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure.
32GF Score
Get the complete analysis for FRA:4RM
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4RM has been successfully added to your 
